RecruitingPhase 2NCT07406633

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)

A Phase 2, Multicenter, Study Evaluating the Efficacy, Safety, Tolerability, Pharmacokinetics of KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GI Stromal Tumor in 1st Line Setting

Sponsor

Kumquat Biosciences Inc.

Enrollment

46 participants

Start Date

Jun 23, 2026

Study Type

INTERVENTIONAL

Conditions

GIST - Gastrointestinal Stromal Tumor GIST GIST Metastatic Cancer Gastro Intestinal Stromal Tumour Gastrointestinal Tumors

Summary

This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST. Imatinib has been approved by the FDA for the treatment of different types of cancer including GIST.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Imatinib (Gleevec) and a drug called KQB198 for people with gist, gist - gastrointestinal stromal tumor, and other related conditions. The study is currently recruiting participants at 16 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGKQB198

Oral KQB198

DRUGImatinib (Gleevec)

Oral Imatinib

Locations(17)

USC Norris Comprehensive Cancer Center

Los Angeles, California, United States

Mayo Clinic - Jacksonville

Jacksonville, Florida, United States

Sylvester Comprehensive Cancer Center

Miami, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

University of Chicago Medical Center

Chicago, Illinois, United States

University of Iowa Health Care

Iowa City, Iowa, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

University of Michigan Hospitals

Ann Arbor, Michigan, United States

Mayo Clinic - Rochester

Rochester, Minnesota, United States

Northwell Health/R.J. Zuckerberg Cancer Center

Lake Success, New York, United States

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

Cleveland Clinic

Cleveland, Ohio, United States

Oregon Health & Science University

Portland, Oregon, United States

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

UT MD Anderson Cancer Center

Houston, Texas, United States

Huntsman Cancer Institute

Salt Lake City, Utah, United States

Fred Hutchinson Cancer Center

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07406633

Related Trials

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT064413315 locations

A Study on Gastrointestinal Cancer Screening Using a Multi-Targeted Combined Detection Model

NCT077121076 locations

A Study of SKB571 in Participants With Gastrointestinal Tumors

NCT07564466

TARGETed Therapy Drug MONITOring in DIGestive Oncology

NCT0544308729 locations

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

NCT0595736728 locations